The diagnostics advisory committee considered evidence on FibroScan for assessing liver fibrosis and cirrhosis from several sources, including an external assessment report and an overview of that ...

PARIS & WALTHAM, Mass.--(BUSINESS WIRE)--Echosens, a high-technology company offering the FibroScan ® family of products, is pleased to announce its strong presence at the upcoming American ...

Professor of Internal Medicine, University of Nebraska, Omaha; Clinical Professor of Medicine, Creighton University, Omaha, Nebraska Establishing the presence of fibrosis or cirrhosis in patients with ...

The Fibroscan test is recognized in the medical community as an established procedure to assess liver fibrosis. It received FDA approval in 2012. A simple probe is placed on the skin in between the ...

PARIS and WESTBOROUGH, Mass., Nov. 10, 2023 /PRNewswire/ -- The American Association for the Study of Liver Disease (AASLD) has released new guidance advocating noninvasive tests like FibroScan® for ...

WESTBOROUGH, Mass., Sept. 8, 2025 /PRNewswire/ -- Echosens, the leader in non-invasive liver diagnostics, is announcing today that the U.S. Food and Drug Administration's (FDA's) Center for Drug ...

Experts say about one in 10 Americans have some form of liver disease like hepatitis, cirrhosis or cancer.Many of those patients would have to undergo a core needle biopsy procedure, which is invasive ...

PARIS--(BUSINESS WIRE)--Echosens, a high-technology company offering the FibroScan family of products, announces the launch of FibroScan 630 Expert, a high-performance elastography engine that ...

Significant weight loss can modify the progression of Nonalcoholic fatty liver disease (NAFLD) with the most convincing evidence coming from bariatric surgery cohorts. Effective ways to non-invasively ...